Labcorp (LH) Stock Price, News & Analysis

Company Overview

Laboratory Corporation of America Holdings, known as Labcorp, is a global life sciences company specializing in comprehensive clinical laboratory services and drug development solutions. Headquartered in Burlington, North Carolina, the company offers a broad range of diagnostics and testing services that support patient care, disease management and biomedical research.

Labcorp’s core services cover routine and specialized clinical testing, anatomic pathology, molecular diagnostics and genomic sequencing. Its drug development division, Covance, provides end-to-end preclinical and clinical research services, including toxicology studies, clinical trial management and regulatory support. Through these offerings, Labcorp enables healthcare providers, biopharmaceutical firms and research institutions to accelerate drug discovery and deliver personalized medicine.

The company operates a network of more than 2,000 laboratories and patient service centers across North America, Europe, Asia-Pacific and Latin America. This global footprint allows Labcorp to partner with hospitals, clinics, academic centers and government agencies to enhance diagnostic capabilities and expand access to testing in key markets around the world.

Founded in 1978 with the formation of its first laboratory business, Labcorp has grown through strategic acquisitions and technology investments. A landmark moment came in 2014 when it acquired Covance, a leading contract research organization, broadening its research and development offerings. Today, Labcorp continues to invest in advanced diagnostics, data analytics and digital pathology to support innovation in precision health and improve patient outcomes.

Key Stats

• Today's Range: $274.94 to $278.48
• 50-Day Range: $242.82 to $279.55
• 52-Week Range: $209.38 to $283.47
• Volume: 379,936 shs
• Average Volume: 496,927 shs
• Market Capitalization: $23.11 billion
• P/E Ratio: 30.69
• Dividend Yield: 1.04%
• Price Target: $290.33
• Consensus Rating: Moderate Buy

Labcorp Stock Analysis - MarketRank™

Labcorp scored higher than 97% of companies evaluated by MarketBeat, and ranked 50th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Labcorp has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 9 buy ratings, 3 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Labcorp has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.56%

Earnings Growth

Earnings for Labcorp are expected to grow by 9.56% in the coming year, from $16.01 to $17.54 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Labcorp is 30.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 83.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Labcorp is 30.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 42.82.

Price to Earnings Growth Ratio

Labcorp has a PEG Ratio of 1.79. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Labcorp has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.32% of the float of Labcorp has been sold short.

Short Interest Ratio / Days to Cover

Labcorp has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Labcorp has recently decreased by 18.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Labcorp pays a meaningful dividend of 1.03%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Labcorp does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Labcorp is 31.79%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Labcorp will have a dividend payout ratio of 16.42% next year. This indicates that Labcorp will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

3.32% of the float of Labcorp has been sold short.

Short Interest Ratio / Days to Cover

Labcorp has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Labcorp has recently decreased by 18.40%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.45

News Sentiment

Labcorp has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for Labcorp this week, compared to 19 articles on an average week.

Search Interest

Only 1 people have searched for LH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Labcorp to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Labcorp insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,831,192.00 in company stock.

Percentage Held by Insiders

Only 0.84% of the stock of Labcorp is held by insiders.

Percentage Held by Institutions

95.94% of the stock of Labcorp is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LH Stock Analysis - Frequently Asked Questions

How have LH shares performed this year?

Labcorp's stock was trading at $229.32 at the beginning of 2025. Since then, LH shares have increased by 21.3% and is now trading at $278.0650.

How were Labcorp's earnings last quarter?

Labcorp Holdings Inc. (NYSE:LH) posted its quarterly earnings data on Thursday, July, 24th. The medical research company reported $4.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.14 by $0.21. The firm's quarterly revenue was up 9.6% on a year-over-year basis.
Read the conference call transcript.

Does Labcorp have any subsidiaries?

The following companies are subsidiaries of Labcorp: Clinical Outreach Laboratory Services, Personal Genome Diagnostics Inc., Toxikon Corporation, Myriad Autoimmune’s Vectra Testing Business, Ovia Health, Visiun, Envigo's nonclinical contract research services business, and others.

Who are Labcorp's major shareholders?

Top institutional shareholders of Labcorp include Vanguard Group Inc. (11.89%), State Street Corp (4.65%), Select Equity Group L.P. (2.57%) and Geode Capital Management LLC (2.54%). Insiders that own company stock include Adam H Schechter, Glenn A Eisenberg, Brian J Caveney, Lance Berberian, Paul R Kirchgraber, Kerrii B Anderson, Dwight Gary Gilliland, Amy B Summy, Mark S Schroeder, Jonathan P Divincenzo, Der Vaart Sandra D Van and Peter J Wilkinson.
View institutional ownership trends.

How do I buy shares of Labcorp?

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Labcorp own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Labcorp investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Record date for 6/11 Dividend: 5/29/2025
• Dividend Payable: 6/11/2025
• Last Earnings: 7/24/2025
• Record date for 9/11 Dividend: 8/28/2025
• Ex-Dividend for 9/11 Dividend: 8/28/2025
• Today: 8/29/2025
• Dividend Payable: 9/11/2025
• Next Earnings (Estimated): 10/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:LH
• Previous Symbol: NYSE:LH?
• CIK: 920148
• Web: www.labcorp.com
• Phone: (336) 229-1127
• Fax: 336-513-4510
• Employees: 75,500
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Labcorp: $290.33
• High Price Target: $311.00
• Low Price Target: $260.00
• Potential Upside/Downside: +4.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.62
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $9.06
• Trailing P/E Ratio: 30.69
• Forward P/E Ratio: 17.37
• P/E Growth: 1.79
• Net Income: $746 million
• Net Margins: 5.66%
• Pretax Margin: 7.23%
• Return on Equity: 15.45%
• Return on Assets: 7.02%

Debt

• Debt-to-Equity Ratio: 0.61
• Current Ratio: 1.50
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $13.01 billion
• Price / Sales: 1.78
• Cash Flow: $22.30 per share
• Price / Cash Flow: 12.47
• Book Value: $101.96 per share
• Price / Book: 2.73

Miscellaneous

• Outstanding Shares: 83,100,000
• Free Float: 82,402,000
• Market Cap: $23.11 billion
• Optionable: Optionable
• Beta: 0.78